Literature DB >> 19308041

Reduced intensity versus full myeloablative stem cell transplant for advanced CLL.

E Peres1, T Braun, O Krijanovski, Y Khaled, J E Levine, G Yanik, K Kato, S Mineishi.   

Abstract

CLL remains incurable with the standard therapy. Allogeneic hematopoietic stem cell transplant may be curative. We examined 50 patients with advanced CLL who underwent allogeneic HCT at the University of Michigan between 1996 and 2006. Twenty-one patients received reduced-intensity conditioning (RIC) and twenty-nine patients received full-intensity conditioning (FIC) consisting of CY, etoposide and BCNU (n=20) or BU and CY (n=9). RIC recipients were older than FIC recipients (median age 54 vs 51, P=0.009). There were no statistically significant differences between groups in terms of the number of earlier therapies or patients with adverse cytogenetics. There were more unrelated donors in the RIC group 62% than in the FIC group 31% (P=0.030). Despite their older age and greater use of URD, the 5-year overall survival (OS) rate was 63% in the RIC group as compared with 18% in the FIC group (P=0.006). The primary cause of inferior survival in the FIC recipients was TRM, which was twice as high at day 100 for the FIC group 27% compared with the RIC group 14% (P=0.005). The relapse rate was 15% regardless with the majority of relapses occurring after day 100. These results suggest a favorable outcome for advanced CLL who undergo a RIC regimen compared with FIC.

Entities:  

Mesh:

Year:  2009        PMID: 19308041     DOI: 10.1038/bmt.2009.61

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  5 in total

Review 1.  Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.

Authors:  Mohamed A Kharfan-Dabaja; Ambuj Kumar; Mehdi Hamadani; Stephan Stilgenbauer; Paolo Ghia; Claudio Anasetti; Peter Dreger; Emili Montserrat; Miguel-Angel Perales; Edwin P Alyea; Farrukh T Awan; Ernesto Ayala; Jacqueline C Barrientos; Jennifer R Brown; Januario E Castro; Richard R Furman; John Gribben; Brian T Hill; Mohamad Mohty; Carol Moreno; Susan O'Brien; Steven Z Pavletic; Javier Pinilla-Ibarz; Nishitha M Reddy; Mohamed Sorror; Christopher Bredeson; Paul Carpenter; Bipin N Savani
Journal:  Biol Blood Marrow Transplant       Date:  2016-09-19       Impact factor: 5.742

Review 2.  Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation.

Authors:  S R Pingali; R E Champlin
Journal:  Bone Marrow Transplant       Date:  2015-05-18       Impact factor: 5.483

3.  High incidence of chronic graft-versus-host disease after myeloablative allogeneic stem cell transplantation for chronic lymphocytic leukemia in Sweden: graft-versus-leukemia effect protects against relapse.

Authors:  Maciej Machaczka; Jan-Erik Johansson; Mats Remberger; Helene Hallböök; Vladimir Lj Lazarevic; Björn Engelbrekt Wahlin; Hamdy Omar; Anders Wahlin; Gunnar Juliusson; Eva Kimby; Hans Hägglund
Journal:  Med Oncol       Date:  2013-11-09       Impact factor: 3.064

4.  Current and emerging treatments for chronic lymphocytic leukaemia.

Authors:  Tadeusz Robak; Krzysztof Jamroziak; Pawel Robak
Journal:  Drugs       Date:  2009       Impact factor: 9.546

5.  Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome.

Authors:  J R Brown; H T Kim; P Armand; C Cutler; D C Fisher; V Ho; J Koreth; J Ritz; C Wu; J H Antin; R J Soiffer; J G Gribben; E P Alyea
Journal:  Leukemia       Date:  2012-08-14       Impact factor: 11.528

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.